| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Myricitrin (Myricitroside), a naturally occurring flavonoid compound isolated from the root bark of Myrica cerifera, is a bioactive compound which exerts antinociceptive effects. Myricitrin produces pronounced antinociception against chemical and mechanical models of pain in rodents via preventing the protein kinase C (PKC) alpha and PKC epsilon activation by phorbol myristate acetate (PMA). Another study proves that opening of voltage- and small-conductance calcium-gated K(+) channels and reduction of calcium influx leads to the antinociceptive of myricitrin.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
J Pharmacol Exp Ther.2006 Feb;316(2):789-96;Eur J Pharmacol.2007 Jul 19;567(3):198-205.
|
||
| Additional Infomation |
Myricitrin is a glycosyloxyflavone that consists of myricetin attached to a alpha-L-rhamnopyranosyl residue at position 3 via a glycosidic linkage. Isolated from Myrica cerifera, it exhibits anti-allergic activity. It has a role as an anti-allergic agent, an EC 1.14.13.39 (nitric oxide synthase) inhibitor, an EC 2.7.11.13 (protein kinase C) inhibitor and a plant metabolite. It is a pentahydroxyflavone, a glycosyloxyflavone, an alpha-L-rhamnoside and a monosaccharide derivative. It is functionally related to a myricetin. It is a conjugate acid of a myricitrin(1-).
Myricitrin has been reported in Castanopsis fissa, Phyllanthus tenellus, and other organisms with data available. |
| Molecular Formula |
C21H20O12
|
|
|---|---|---|
| Molecular Weight |
464.38
|
|
| Exact Mass |
464.095
|
|
| CAS # |
17912-87-7
|
|
| Related CAS # |
|
|
| PubChem CID |
5281673
|
|
| Appearance |
White to yellow solid powder
|
|
| Density |
1.9±0.1 g/cm3
|
|
| Boiling Point |
896.6±65.0 °C at 760 mmHg
|
|
| Melting Point |
197 °C
|
|
| Flash Point |
315.7±27.8 °C
|
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
|
| Index of Refraction |
1.805
|
|
| LogP |
1.98
|
|
| Hydrogen Bond Donor Count |
8
|
|
| Hydrogen Bond Acceptor Count |
12
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
33
|
|
| Complexity |
760
|
|
| Defined Atom Stereocenter Count |
5
|
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C(=C4)O)O)O)O)O)O
|
|
| InChi Key |
DCYOADKBABEMIQ-OWMUPTOHSA-N
|
|
| InChi Code |
InChI=1S/C21H20O12/c1-6-14(26)17(29)18(30)21(31-6)33-20-16(28)13-9(23)4-8(22)5-12(13)32-19(20)7-2-10(24)15(27)11(25)3-7/h2-6,14,17-18,21-27,29-30H,1H3/t6-,14-,17+,18+,21-/m0/s1
|
|
| Chemical Name |
3-[(6-deoxy-α-L-mannopyranosyl)oxy]-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1534 mL | 10.7670 mL | 21.5341 mL | |
| 5 mM | 0.4307 mL | 2.1534 mL | 4.3068 mL | |
| 10 mM | 0.2153 mL | 1.0767 mL | 2.1534 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA